Navigation Links
Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
Date:12/17/2009

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

The new Special European Physician & Payer Forum report entitled Targeted Therapies for NSCLC: How High are the Barriers to Displacing Avastin in Europe? finds that Avastin, which is not recommended for use within the United Kingdom's National Health Service, is used more often for non-small-cell lung cancer in the first and second line in France and Germany than in Italy and Spain. However, over the next 12 months, surveyed oncologists in Italy and Spain expect to increase first-line use of targeted agents such as Avastin, OSI Pharmaceuticals/Roche/Chugai's Tarceva and AstraZeneca's Iressa. According to the report, Tarceva is the second-most commonly prescribed targeted therapy in the first line after Avastin.

While Avastin, Tarceva and Iressa have shown modest efficacy in select patient populations, other agents in late-stage development have struggled to reach the non-small-cell lung cancer drug market. Three targeted therapies -- Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux, AstraZeneca's Zactima and Pfizer's figitumumab -- experienced recent setbacks in ongoing Phase III clinical trials or in receiving approval from the European Medicines Agency.

"The landscape for non-small-cell lung cancer will shift over the next several years as oncologists and payers grapple with the role of maintenance/consolidation therapy, increasing uptake of targeted therapies in the first-line setting and with the potential launch of new biologic agents," said Decision Resources Director Madhuri Borde, Ph.D.

The report also finds that cost-sharing schemes for targeted therapies -- which have been negotiated by the Italian Medicines Agency for both Avastin and Tarceva -- are much more prevalent in Italy than in the other European countries surveyed. Negotiating cost-sharing schemes is one of several factors that can contribute to delayed uptake of targeted therapies in Italy. Other factors include the time the agency spends reviewing new drug applications, setting prices and the requirement that new drugs must be accepted onto both regional and hospital formularies prior to their use.

Targeted Therapies for NSCLC: How High are the Barriers to Displacing Avastin in Europe? is based on surveys with 224 oncologists and interviews with 20 hospital-based payers in Germany, France, Italy, Spain and the United Kingdom. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563
    ccomfort@dresources.com                   emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
2. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
5. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
6. European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient
7. A Drugs Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections
8. Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8
9. Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
10. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
11. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Market 2016-2020" report to their offering. ... The global artificial pancreas devices system ... 2016-2020. Global Artificial Pancreas Devices System Market 2016-2020, has ... industry experts. The report covers the market landscape and its growth ...
(Date:1/17/2017)... 17, 2017 The interventional radiology products market ... from USD 6.35 billion in 2016, at a CAGR ... of this market are rising incidence of chronic diseases, ... surgeries. The global interventional radiology products market ... On the basis of type, the stents segment is ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
Breaking Medicine Technology:
(Date:1/17/2017)... Tampa, Fla (PRWEB) , ... January 17, 2017 , ... ... IT Excellence Award for Innovation of the Year. , Each year, Pink ... has taken an innovative approach to address a specific business problem or opportunity. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... visualize, detect, and eliminate cyber threats in real-time, today announced a strategic partnership ... headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader ... new agreement as part of a long-term extension of their media partnership. The partnership, ... of some of the sport’s premier events exclusively on FloWrestling.com as well as usage ...
Breaking Medicine News(10 mins):